- Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
- Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinibTan, Daniel Shao-Weng; Kim, Tae Min; Guarneri, Valentina; Voon, Pei Jye; Lim, Boon Khaw; Wislez, Marie; Huang, Cheng; Liam, Chong Kin; Mazieres, Julien; Tho, Lye Mun; Hayashi, Hidetoshi; Nhung, Nguyen; Chia, Puey Ling; De Marinis, Filippo; Le, Xiuning; Karachaliou, Niki; Brutlach, Sabine; Adrian, Svenja; Ellers-Lenz, Barbara; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterationsYang, J-J.; Zhang, Y.; Wu, L.; Hu, J.; Wang, Z-H.; Chen, J-H.; Fan, Y.; Lin, G.; Wang, Q-M.; Yao, Y.; Zhao, J.; Chen, Y.; Fang, J.; Song, Y.; Zhang, W.; Cheng, Y.; Guo, R-H.; Li, X-Y.; Li, A-N.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study
1被引4阅读
